is being presented by Dr. Malgorzata Szerszeniewska, CEO, of Easthorn Clinical Services in CEE and airs on Wednesday, March 24, 2010. For more details or to register, please visit our site at www.fxconferences.com
It has recently been shown that the cost of clinical trials may play a crucial role in the drug development process. A lot of the most innovative biotech companies struggled financially last year and many programs have been put on hold or cancelled due to cash flow problems. A lot of companies have had difficulties in finding partners to help them financially to complete even very promising programs. That is why the cost of conducting clinical trials has become one of the major factors for pharma companies’ drug development strategies, their pipelines, and their CRO selection criteria. As market volume shrank CROs had to compete for fewer studies and price has become an important selection criterion.
This presentation provides a comparison of clinical trial costs in central and eastern europe and other representative regions. Our speaker addresses a variety of factors influencing the costs and discusses the dynamics and directions of recent changes. This information is of use in future budget planning, strategic country selection for specific clinical trials and minimizing financial surprises while running trials in CEE.
